May the activation of mast cells by IgG-food antigen complexes be the missing piece of irritable bowel syndrome puzzle?

Abstract

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders with multifactorial pathophysiology such as visceral hypersensitivity, intestinal dysmotility, brain-gut axis dysregulation, altered intestinal fluid secretion, impaired permeability, mucosal immune dysregulation, bacterial dysbiosis and psychological stress. Recent studies have suggested that activation of intestinal mast cells may play a role in many of these factors. On the other hand, from the beginning of this century, symptomatic improvements by elimination of foods with increased IgG antibodies have been reported in patients with IBS. These results may be explained by decreased activation of intestinal mast cells due to decreased IgG-food antigen immune complexes. Immune complex mediated mast cell activations occur when they bind to activating IgG receptors (FcγRs). If these antigens belong to some of the commonly consumed foods such as gluten-containing grains, bread yeast, cow’s milk and products, chicken egg or food additives like thickening agents, mast cell activations increase and may cause the disease to be treatment resistant. In this article, the role of increased IgG-food antigen complex dependent mast cell activation in the pathogenesis of IBS will be discussed.

Keywords: irritable bowel syndrome, mast cells, food-specific IgG antibodies, food additives

Introduction

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, bloating, altered bowel habits, flatulence, urgency or straining to stool, and feeling of incomplete evacuation which may differ from patient to patient. Symptom severity also varies in patients, in a way from tolerable to severe which is markedly impairing patients’ quality of life.

Irritable bowel syndrome is a multifactorial disease, the pathophysiological mechanisms are complex and have not been completely understood. Visceral hypersensitivity, intestinal dysmotility, impaired gut barrier function, altered intestinal fluid secretion, brain-gut axis dysregulation, mucosal immune alterations, bacterial dysbiosis and genetic, dietary, psychological factors have been suggested.\(^1\) \(^2\) Recently, presence of low-grade intestinal mucosal inflammation, rich in mast cells which are mainly activated, has focused the attention to IBS and mast cell association. In a new systematic review, significantly increased mucosal mast cell counts/or density in IBS patients was observed in 30 of the 36 case-control studies evaluated.\(^3\) Many studies have supported that mediators released from the activation of mast cells play an important role for most of the abnormalities seen in IBS such as visceral hypersensitivity,\(^4\) \(^5\) altered secretion,\(^6\) \(^7\) disturbed motility,\(^8\) \(^9\) increased intestinal permeability.\(^10\) \(^11\) \(^12\) Local microenvironment in the gut lumen such as commensal bacteria and products, food antigens, allergens and toxins are able to activate mast cells. Mast cells are also activated by psychologic distress and negative life events.\(^2\)

On the other hand, many patients with IBS have histories of adverse food reactions.\(^13\) \(^14\) Some of them modify their diet by excluding self-identified foods, and a few of them have to feed themselves with a very limited number of foods. Although food related symptoms in IBS are well-known, the underlying mechanisms have not been fully understood. Though, poorly absorbed fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) related luminal distension,\(^15\) IgE-mediated food allergy due to mast cell activation and food intolerances from enzyme deficiencies\(^16\) \(^17\) have been known. Recently it has been understood that some patients with IBS may have non-celiac gluten sensitivity.\(^18\)

Since 2004, some studies have been reported symptomatic improvements with the elimination of foods having increased IgG antibody levels (IgG positive foods) in patients with IBS.\(^19\) \(^20\) The mechanisms of these results have not been considered to be associated with mast cells. However, some of these improvements can be explained by diminished mast cell activations because of decreased IgG-food antigen immune complexes, due to lack of antigen part of them.\(^21\)

IgG antibody mediated activation of mast cells was shown in 1969 and IgG receptors (FcγRs) were described on these cells in 1971.\(^22\) Because of the most receptors for IgG antibodies in humans are in mast cells due to decreased IgG-food antigen immune complexes, due to lack of antigen part of them.\(^21\)

In this paper, the role of increased mast cell activation by immune complexes, formed IgG-food and food additive antigens...
emphasized as one of the pathogenetic factors in IBS.

**Mast cells**

Mast cells have a widespread distribution and are found predominantly at barrier sites of the body such as the skin, gastrointestinal, respiratory and urinary tracts. Recently, it has been realized that mast cells are multifunctional immune cells implicated in several health and disease conditions. Mast cells are involved in physiological processes and maintain integrity/function in all tissues. They play a pivotal role in innate and adaptive immunity and immune tolerance. They also have an important role in the pathogenesis of several disorders.

Many stimuli, such as IgE, IgG, IgA, complements, TLR ligands, cytokines, chemokines and other inflammatory products, certain drugs, physical factors can activate mast cells. Substance P, corticotropin releasing hormone (CRH) and estrogens, likewise xenoestrogens which have estrogen-like activities can also activate mast cells. Upon activation, mast cells release preformed mediators stored in the granules (e.g., histamine, heparin, serotonin, tryptase, chymase) and newly synthesised mediators (e.g., prostaglandins, leukotrienes, cytokines, chemokines and growth factors) through classic non-selective degranulation or selective mediator release. Preformed mediators such as histamine and heparin cause many changes, seen in early-phase allergic reactions and newly synthesized mediators cause inflammation with attracting leukocytes to the inflammatory site.

**Mast cell-IBS relationship**

Mast cells are common residents of the intestine, mainly located in the lamina propria (2–3% of all cells) and slightly less in the submucosa (1% of all cells). They are also found in the intraepithelial, smooth muscle and serosal layers. Mast cells communicate with the adjacent epithelial, neuronal, smooth muscle and other immune cells when they are activated. There are close proximity and crosstalk between neuronal units (enteric nerves and extrinsic nerve fibers) and mast cells. Mast cells involve in physiological processes of the intestine such as regulating permeability, secretion, peristalsis, and host defense mechanisms against pathogens. These physiological responses are related to the releasing bioactive mediators into adjacent tissues as the result of stimulation of mucosal mast cells both IgE/antigen-dependent and non-IgE-dependent ways.

In many of studies, mast cells have been shown to be increased in number and activation in both small and large bowels in patients with IBS. They can be responsible for many of the pathophysiological factors of IBS with their mediators, released by activation. Studies with mast cell mediators (mainly histamine and tryptase) showed increasing excitability of senso-secretory-motor neurons leading to visceral hypersensitivity, altering secretion and disturbing motility. Increased intestinal permeability and tryptase related degradation of the junctional proteins between intestinal epithelial cells were also detected. Activation of intestinal mast cells can cause low grade mucosal inflammation and the inflammation might also be responsible for both visceral hypersensitivity and epithelial barrier dysfunction.

On the other hand, it is well known that stressful life events are associated with onset or exacerbation of IBS symptoms. CRH which is induced by psychological stress, is one of the factor for mast cell degranulation. Stress enhanced abdominal contractions involving central CRH and intestinal mast cells were shown in rats. In humans, increased intestinal permeability via CRH-mediated mast cell activation due to acute psychological stress was also shown. Finally, ketotifen treatment which prevents mast cell degranulation was found highly effective for the symptomatic improvement in patients with IBS.

**Adverse food reactions in IBS related mast cell activation**

Food chemicals, such as some additives (e.g., benzoate, sulphite), naturally occurring salicylates and biogenic amines (e.g., histamine) may provoke some symptoms and some of them related to the gastrointestinal system. Several mechanisms have been proposed to explain the pathogeneses of these symptoms, including non-immune direct activation of mast cells. Besides, pesticides, a group of xenoestrogens are very common as environmental pollutants and present in mainly water and foods, can activate mast cells mostly mediated by estrogen receptors α.

Food hypersensitivity (allergy) is an adverse immune response to food and can be classified as IgE-mediated and non-IgE-mediated (delayed or cell-mediated) reactions. IgE-mediated allergy is well-known and associated with mast cells but not common in IBS.

**Food sensitivity and IBS**

Recently IgG antibody dependent mast cell activation has been classified as allergy and it has been suggested that it is common for food and food additives. IgG-antigen immune complexes can activate mast cells when they bind to activating FcγRs. This type of reaction might observed in patients with IBS. Because from beginning of this century, the number of studies giving symptomatic improvements in patients with IBS by elimination of foods, having higher IgG antibody levels above the cut-off value of healthy people, has reached five. The terms such as food sensitivity, food intolerance and even IgG-mediated food hypersensitivity have been used for this type of reaction. Now, two different IgG antibody testings are available, while IgG4 testing measures only the amount of IgG4 antibodies, a subclass of IgG antibodies. IgG testing gives total amount of four subclasses of them. Four of these studies used IgG, one used IgG4 testings.

Results of these clinical studies suggest the relationship between IBS and IgG positive foods. In case this finding and the growing knowledge for IBS-mast cell association are evaluated together, IgG-food antigen immune complex related mast cell activation can be thought as one of the factors for the pathogenesis of IBS. Consequently, increased IgG antibody titers can help for the selection of eliminated foods. In addition, some kind of food additives, such as thickening agents may be the subject of IgG-mediated mast cell activation. In the light of my experience, almost half of the patients with IBS have increased IgG antibodies for agar (E406), carrageenan (E407), and guar gum (E412).

On the other hand, the relationship between increased food specific IgG antibodies and adverse food reactions has been opposed by some authors. They concluded that the antibodies were present as the result of the physiologic response of the immune system, thereby reflecting exposure to foods and food tolerance. Actually food-specific IgG antibodies are available in healthy individuals. The food tolerance is defined as the specific suppression of humoral and/or cellular immune responses to prevent unnecessary immune reactions to innocuous...
dietary antigens. For this reason, presence of the antibodies against the food antigens in low levels may be explained by food tolerance. The increase in the amount of IgG antibodies above normal upper limits for some foods, may be due to loss of tolerance against them. As a result, the immune system may recognize these food antigens as foreign ones and begin to produce antibodies against them. Perhaps their presence in low amounts may be necessary for physiological functions of mast cells.

Some objections have been focused on food specific IgG4 antibody testing. Naturally, food-specific IgG antibodies are detected in healthy people with frequently presence of IgG4 subclass. Currently, IgG4 antibodies have been accepted as “blocking antibodies” especially in the context of allergies. Because IgG4 antibodies have low affinity to activating FcyRs and high affinity to inhibitory FcγRIIB, they can prevent excessive immune responses against sterile antigens. Interestingly, in addition to the IBS study, two Crohn study reaching symptomatic and laboratory improvements with elimination of IgG4 positive foods were reported. Their good results can be explained by the presence both IgG and IgG4 positivity for some of the same food antigens especially the ones consumed frequently such as gluten, yeast, milk and products, egg and thickening food additives. These topic needs to be investigated with exclusion diet studies comparing IgG and IgG4 subclasses.

Furthermore, all IgG positive foods do not cause symptoms. In a Chinese population study, chronic symptoms showed positive correlation with the concentration of some food-specific IgG antibodies, while others did not. This finding can be explained that some IgG-antigen complexes may not activate mast cells because they can bind inhibiting Fcγ receptors. This possibility can be excluded by provocation for each IgG positive food after the patient becomes symptomless with elimination diet.

**Conclusion**

In recent years, numerous studies have revealed that mast cells play a role in both the physiological processes of the intestine and the pathophysiological factors of IBS such as visceral hypersensitivity, dysmotility, mucosal barrier disruption, altered intestinal fluid secretion and mucosal immune dysregulation. Additionally, presence of degranulated mast cell rich low grade intestinal inflammation in patients with IBS has focused the attention to IBS and mast cell association. Since the intestinal mucosa is mainly exposed to food and bacterial antigens, it is natural that food reactions due to mast cell activation may be part of this inflammation.

However, IgE-mediated mast cell activation (food allergy) is not common in IBS, symptomatic improvements with the elimination of foods having increased IgG levels suggest the activation of mast cells by IgG-food and additive antigen complexes. This type of activation may be a common factor in the pathogenesis of some IBS patients and can be considered as the missing piece of puzzle. Food-specific IgG antibody levels seem to help in selecting foods to be restricted. Other common mast cell activators are naturally occurring and added food chemicals and xenoestrogens. It should be noted that psychological stress and bacterial antigens and products are also among mast cell stimulants in IBS.

In the future, elimination of dietary and other mast cell activators using with mast cell stabilizers may give more promising results for the treatment of IBS.

**Acknowledgments**

None.

**Conflicts of interest**

The author has no conflicts to declare.

**Funding**

None.

**References**

1. Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. *Gastroenterol Res Pract*. 2016;2016:2031480.
2. Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. *J Neurogastroenterol Motil*. 2016;22(1):181–192.
3. Krammer L, Sowa AS, Lorenz A. Mast Cells in Irritable Bowel Syndrome: A Systematic Review. *J Gastrointestin Liver Dis*. 2019;28(4):463–472.
4. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology*. 2004;126(3):693–702.
5. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral–nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology*. 2007;132(1):26–37.
6. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. *J Gastroenterol Hepatol*. 2006;21(1 Pt 1):71–78.
7. Crowe SE, Luthra GK, Perdue MH. Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease. *Gut*. 1997;41(6):785–792.
8. Castro GA, Harari Y, Russell D. Mediators of anaphylaxis–induced ion transport changes in small intestine. *Am J Physiol*. 1987;253(4 Pt 1):G540–G548.
9. Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. *Neurogastroenterol Motil*. 2012;24(12):e1187–e1187.
10. Martinez C, Vicario M, Ramos L, et al. The jejunum of diarrhea–predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. *Am J Gastroenterol*. 2012;107(5):736–746.
11. Martinez C, Lobo B, Pigras M, et al. Diarrhoea–predominant irritable bowel syndrome:an organic disorder with structural abnormalities in the jejunal epithelial barrier. *Gut*. 2013;62(2):1160–1168.
12. Wilcz–Villega EM, McClean S, O’Sullivan MA. Mast cell tryptase reduces junctional adhesion molecule–A (JAM–A) expression in intestinal epithelial cells:implications for the mechanisms of barrier dysfunction in irritable bowel syndrome. *Am J Gastroenterol*. 2013;108(7):1140–1151.
13. Cuomo R, Andreozzi P, Zito FP, et al. Irritable bowel syndrome and food interaction. *World J Gastroenterol*. 2014;20(27):8837–8845.
14. Shepherd SJ, Lomer MC, Gibson PR. Short–chain carbohydrates and functional gastrointestinal disorders. *Am J Gastroenterol*. 2013;108(5):707–717.
May the activation of mast cells by IgG-food antigen complexes be the missing piece of irritable bowel syndrome puzzle?

15. Choung RS, Talley NJ. Food Allergy and Intolerance in IBS. Gastroenterol Hepatol (NY). 2006;2(10):756–760.

16. Barmeyer C, Schumann M, Meyer T, et al. Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. Int J Colorectal Dis. 2017;32(1):29–39.

17. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459–1464.

18. Zar S, Mincher L, Benson MJ, et al. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40(7):800–807.

19. Yang CM, Li YQ. The therapeutic effects of elimination allergic foods according to food-specific IgG antibodies in irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2007;46(8):641–643.

20. Guo H, Jiang T, Wang J, et al. The value of eliminating foods according to food specific immunoglobulin G antibodies in irritable bowel syndrome with diarrhea. J Int Med Res. 2012;40(1):204–210.

21. Aydinalar EL, Dikmen PY, Tiftikci A, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514–525.

22. Uzunismail H. Possible Mechanism of Symptomatic Improvement with IgG Antibody–Guided Exclusion Diet in Inflammatory Bowel Disease and Irritable Bowel Syndrome. J Inflamm Bowel Dis Disor. 2018;3:2.

23. Jönsson F, Daëron M. Mast cells and company. Front Immunol. 2012;3:16.

24. da Silva EZ, Jamur MC, Oliver C. Mast cell function:a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698–738.

25. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21–33.

26. Narita S, Goldblum RM, Watson CS, et al. Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators. Environ Health Perspect. 2007;115(1):48–52.

27. He SH, Zhang HY, Zeng XN, et al. Mast Cells and basophils are essential for allergies: mechanisms of allergic inflammation and aproposed procedure for diagnosis. Acta Pharmacol Sin. 2013;34(10):1270–1283.

28. Bischoff SC, Wedemeyer J, Herrmann A, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology. 1996;28(1):1–13.

29. Yu LC, Perdue MH. Role of mast cells in intestinal mucosal function: studies in models of hypersensitivity and stress. Immunol Rev. 2001;179:61–73.

30. Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta. 2012;1822(1):85–92.

31. Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology. 1989;97(3):575–585.

32. Bischoff S. C. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol. 2009;31(2):185–205.

33. Gué M, Del Rio–Lacheze C, Eutamene H, et al. Stress–induced visceral hypersensitivity to rectal distension in rats:role of CRF and mast cells. Neurogastroenterol Motil. 1997;9(4):271–279.

34. Vanuytsel T, van Wanrooy S, Vanhee H. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell–dependent mechanism. Gut. 2014;63(8):1293–1299.

35. Kloofer TK, Braak B, Koopman KE, et al. The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213–1221.

36. Carr S, Chan E, Lavine E, Moote W. CSACI Position statement on the testing of food–specific IgG. Allergy Asthma Clin Immunol. 2012;8(1):12.

37. Husby S, Oxcellus VA, Teisner B, et al. Humoral immunity to dietary antigens in healthy adults. Occurrence, isotype and IgG subclass distribution of serum antibodies to protein antigens. Int Arch Allergy Appl Immunol. 1985;77(4):416–422.

38. Faria AM, Weiner HL. Oral tolerance. Immunol Rev. 2005;206:232–259.

39. Vojdani A. Molecular mimicry as a mechanism for food immune reactivities and autoimmunity. Altern Ther Health Med. 2015;21 Suppl 1:34–45.

40. Stapel SO, Asero R, Ballmer–Weber BK, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy. 2008;63(7):793–796.

41. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.

42. Rajendran N, Kumar D. Food–specific IgG4-guided exclusion diets improve symptoms in Crohn’s disease: a pilot study. Colorectal Dis. 2011;13(9):1009–1103.

43. Gunasekera V, Mendall MA, Chan D, et al. Treatment of Crohn’s Disease with an IgG4-Guided Exclusion Diet: A Randomized Controlled Trial. Dig Dis Sci. 2016;61(4):1148–1157.

44. Zeng Q, Dong SY, Wu LX, et al. Variable food–specific IgG antibody levels in healthy and symptomatic Chinese adults. PLoS One. 2013;8(1):e53612.